James M. Carroll
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
James M. Carroll has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Edward Brian Garon
Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, USA
2 shared publications - Kai Chang
Zhejiang University
2 shared publications - Ahmet Zehir
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, USA
1 shared publication - Amy L. Cummings
David Geffen School of Medicine at the University of California, Los Angeles, USA
1 shared publication - Annette L. Stanton
University of California Los Angeles
1 shared publication Benjamin Greenbaum
Tisch Cancer Institute, Departments of Medicine, Oncological Sciences, and Pathology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
1 shared publication
Latest Publications
- Open Access
- 1 December 2018
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 2 (2) , 1-12
Low Concordance of Patient-Reported Outcomes With Clinical and Clinical Trial Documentation
Purpose: Health care research increasingly relies on assessment of data extracted from electronic medical records (EMRs). Clinical trial adverse event (AE) logs and patient-reported outcomes (PROs) are sources of data often available in the context of specific research projects. The aim of this study was to evaluate the extent of data concordance from these sources. Patients and Methods: Patients enrolled in clinical trials or receiving standard treatment for lung cancer (n = 62) completed validated questionnaires on physical and psychological symptoms at up to three assessment points. Temporally matched documentation was extracted from EMR notes and, for clinical trial participants (n = 41), AE logs. Evaluated data included symptom assessment, vital signs, medication logs, and laboratory values. Agreement (positive, negative) and Cohen’s κ coefficients were calculated to assess concordance of symptoms among sources, with PROs considered the gold standard. Results: Patient-reported weight loss correlated significantly with clinical measurements ( t = 2.90; P = .02), and average number of PROs correlated negatively with albumin concentration, supporting PROs as the gold standard. Comparisons of PROs versus EMR yielded poor concordance across 11 physical symptoms, anxiety, and depressive symptoms (all κ < 0.40). Providers under-reported the presence of each symptom in the EMR compared with PROs. AE logs showed similarly poor concordance with PROs (all κ < 0.40, except shortness of breath). Negative agreement among sources was higher than positive agreement for all symptoms except pain. Conclusion: There was poor concordance between EMR notes and AE logs with PROs. Findings suggest that EMR notes and AE logs may not be reliable sources for capturing physical and psychological symptoms experienced by patients with lung cancer, supporting use of PRO assessments in oncology practices.
- 1 December 2018
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 2 (2) , 1-12
Open AccessLow Concordance of Patient-Reported Outcomes With Clinical and Clinical Trial Documentation
Purpose: Health care research increasingly relies on assessment of data extracted from electronic medical records (EMRs). Clinical trial adverse event (AE) logs and patient-reported outcomes (PROs) are sources of data often available in the context of specific research projects. The aim of this study was to evaluate the extent of data concordance from these sources. Patients and Methods: Patients enrolled in clinical trials or receiving standard treatment for lung cancer (n = 62) completed validated questionnaires on physical and psychological symptoms at up to three assessment points. Temporally matched documentation was extracted from EMR notes and, for clinical trial participants (n = 41), AE logs. Evaluated data included symptom assessment, vital signs, medication logs, and laboratory values. Agreement (positive, negative) and Cohen’s κ coefficients were calculated to assess concordance of symptoms among sources, with PROs considered the gold standard. Results: Patient-reported weight loss correlated significantly with clinical measurements ( t = 2.90; P = .02), and average number of PROs correlated negatively with albumin concentration, supporting PROs as the gold standard. Comparisons of PROs versus EMR yielded poor concordance across 11 physical symptoms, anxiety, and depressive symptoms (all κ < 0.40). Providers under-reported the presence of each symptom in the EMR compared with PROs. AE logs showed similarly poor concordance with PROs (all κ < 0.40, except shortness of breath). Negative agreement among sources was higher than positive agreement for all symptoms except pain. Conclusion: There was poor concordance between EMR notes and AE logs with PROs. Findings suggest that EMR notes and AE logs may not be reliable sources for capturing physical and psychological symptoms experienced by patients with lung cancer, supporting use of PRO assessments in oncology practices.
- Top Cited Papers
- 2 February 2018
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 359 (6375) , 582-587
Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
HLA genotype affects response: Immunotherapy works by activating the patient's own immune system to fight cancer. For effective tumor killing, CD8 + T cells recognize tumor peptides presented by human leukocyte antigen class I (HLA-I) molecules. In humans, there are three major HLA-I genes ( HLA-A, HLA-B , and HLA-C ). Chowell et al. asked whether germline HLA-I genotype influences how T cells recognize tumor peptides and respond to checkpoint inhibitor immunotherapies (see the Perspective by Kvistborg and Yewdell). They examined more than 1500 patients and found that heterozygosity at HLA-I loci was associated with better survival than homozygosity for one or more HLA-I genes. Thus, specific HLA-I mutations could have implications for immune recognition and for the design of epitopes for cancer vaccines and immunotherapies. Science , this issue p. 582 ; see also p. 516
- 2 February 2018
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 359 (6375) , 582-587
Top Cited PapersPatient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
HLA genotype affects response: Immunotherapy works by activating the patient's own immune system to fight cancer. For effective tumor killing, CD8 + T cells recognize tumor peptides presented by human leukocyte antigen class I (HLA-I) molecules. In humans, there are three major HLA-I genes ( HLA-A, HLA-B , and HLA-C ). Chowell et al. asked whether germline HLA-I genotype influences how T cells recognize tumor peptides and respond to checkpoint inhibitor immunotherapies (see the Perspective by Kvistborg and Yewdell). They examined more than 1500 patients and found that heterozygosity at HLA-I loci was associated with better survival than homozygosity for one or more HLA-I genes. Thus, specific HLA-I mutations could have implications for immune recognition and for the design of epitopes for cancer vaccines and immunotherapies. Science , this issue p. 582 ; see also p. 516
- 27 October 1994
- Published by Institution of Engineering and Technology (IET) in Electronics Letters
- Vol. 30 (22) , 1861-1862
Microstrip mode suppression ring resonator
A novel ring resonator topology was developed which exhibits mode suppression characteristics. The resonator achieves the mode suppression by incorporation of a stepped impedance lowpass filter directly into the ring resonator. Experimental results show that complete suppression of a ring resonator's second mode can be achieved with no increase in circuit size. The topology effectively increases the rejection bandwidth of the ring resonator.
- 27 October 1994
- Published by Institution of Engineering and Technology (IET) in Electronics Letters
- Vol. 30 (22) , 1861-1862
Microstrip mode suppression ring resonator
A novel ring resonator topology was developed which exhibits mode suppression characteristics. The resonator achieves the mode suppression by incorporation of a stepped impedance lowpass filter directly into the ring resonator. Experimental results show that complete suppression of a ring resonator's second mode can be achieved with no increase in circuit size. The topology effectively increases the rejection bandwidth of the ring resonator.
- 21 July 1994
- Published by Institution of Engineering and Technology (IET) in Electronics Letters
- Vol. 30 (15) , 1195-1196
Slotcoupling of coplanar waveguide to patch antennassuitable for MMIC applications
A new design for coupling coplanar waveguide (CPW) to microstrip antennas has been developed. The coupling method consists of direct aperture coupling from the coplanar waveguide feed to the microstrip antenna. The advantage of this method is the use of a single substrate for the entire CPW and antenna circuit as opposed to previous methods of coupling in which multilayer substrates were used.
- 21 July 1994
- Published by Institution of Engineering and Technology (IET) in Electronics Letters
- Vol. 30 (15) , 1195-1196
Slotcoupling of coplanar waveguide to patch antennassuitable for MMIC applications
A new design for coupling coplanar waveguide (CPW) to microstrip antennas has been developed. The coupling method consists of direct aperture coupling from the coplanar waveguide feed to the microstrip antenna. The advantage of this method is the use of a single substrate for the entire CPW and antenna circuit as opposed to previous methods of coupling in which multilayer substrates were used.